Product imageResearch use only

CAT. NO. DC68227Featured

E20

Research highlights

Charge-switching ionizable lipidmRNA and plasmid-DNA deliveryLiterature-reported low immunostimulatory activityAcute lung injury research

Pack size & price

USD

Add the cited formulation componentsSelected E20 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$750

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

E20 is a charge-switching ionizable lipid developed for efficient nucleic acid delivery with reduced inflammatory toxicity. Its carboxylic acid–tertiary amine headgroup changes charge between acidic formulation conditions and physiological pH, while two hydroxylated spacers and branched 8×6 hydrophobic tails support nucleic acid encapsulation and cytosolic delivery. E20 nanoparticles generated approximately 600 mU/mL serum hEPO after intravenous mRNA administration in mice. Unlike multiple benchmark LNPs, E20 did not exacerbate cytokine production in LPS-pretreated mice or human PBMCs. E20 also enabled sustained pDNA expression without the acute lethality observed with MC3-LNPs and improved IL-22 mRNA treatment in a mouse model of acute lung injury.

CAS No.	Not available
Chemical Name	E20
Synonyms	S-lipid E20, Lipid E20, E20 S-lipid
SMILES	CCCCCCCCC(CCCCCC)OC(=O)CCCCCCC(O)CN(CCCCCCC(=O)O)CC(O)CCCCCCC(=O)OC(CCCCCC)CCCCCCCC
Formula	C55H107NO8
M.Wt	910.46
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Liang D, Qi Y, Han H, et al. Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. Published online September 8, 2026.

Literature-reported formulation composition

Component	mol%	Role
E20	35.9	Ionizable lipid
DOPE	24.2	Helper phospholipid
Cholesterol	38.7	Sterol
DMG-PEG2000	1.2	PEG lipid
Reported total	100	Source values retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
E20	35.900	52.2845	47.6029
DOPE	24.200	35.2447	26.2231
Cholesterol	38.700	56.3624	21.7925
DMG-PEG2000	1.200	1.7477	4.3814

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratio4.1

Total lipid:cargo weight ratio21:1 to 24:1 total lipids:mRNA

Buffer & pHmRNA in 10 mM citrate buffer, pH 4.0; dialysed against PBS, pH 7.4

CargohEPO mRNA

Administration routeIntravenous injection (retro-orbital IV)

Dose0.1 mg mRNA/kg, single dose

Animal modelWild-type BALB/c mice, 10-16 weeks old, 18-20 g

Formulation processMicrofluidic mixing with aqueous phase at 3 mL/min and ethanolic lipid phase at 1 mL/min, followed by dialysis against 1,000-fold excess PBS at 4 °C for 2-4 h

Literature-reported performance for the cited formulation

Literature-reportedApparent SNP pKa4.99R18 fluorescence assay · pKa for becoming neutralMain article Figure 2b; SI Section 5.4

Literature-reportedHydrodynamic diameter90-100 nmPost-formulation DLS characterization · Range reported for the five top SNPs E3, E7, E12, E15 and E20; not an E20-only exact valueSI Figure S76 and text, p. 135

Literature-reportedPolydispersity index<0.2Post-formulation DLS characterization · Reported for the SNP formulation panel; not an E20-only exact valueSI Figure S77 and text, p. 135

Literature-reportedBlood hEPO concentration600 mU/mL24 h after 0.1 mg/kg IV hEPO mRNA · Reported as equivalent to MC3-DLin LNPs and 100-fold above the cited therapeutic thresholdMain article Figure 3b and text

Literature-reportedInflammatory cytokine responseNo increase in IL-6, IL-1β or MIP-24 h after 1 mg/kg IV luciferase mRNA in LPS-pretreated mice · Traditional LNP comparators increased the measured cytokines in the LPS-pretreated modelMain article Figure 3c-f; SI Figures S95-S97

Literature-reportedpDNA study survivalAll E20-SNP-treated mice survived the 7-day observation periodAfter 1 mg/kg IV luciferase nanoplasmid DNA · All MC3-DLin LNP-pDNA-treated mice died within 24 hMain article Figure 3g-i and text; SI Section 6.2

Additional reported findings

Human PBMC study

E20-SNPs efficiently delivered luciferase mRNA to human PBMCs and did not induce any of the 14 cytokines evaluated in the reported experiment.

Human PBMCs from four donors; 2,000 ng/mL mRNA; 24 h · Main article Figure 4; SI Figures S90-S93

Acute lung injury study

E20-SNPs carrying IL-22 mRNA were reported to be more effective than the traditional LNP comparators in the LPS-induced acute-lung-injury model without exacerbating pre-existing inflammation.

BALB/c mice; 3 mg/kg intratracheal LPS followed 3 h later by 2.5 mg/kg intratracheal LNP/IL-22 mRNA · Main article acute-lung-injury section; SI Section 6.4

Charge-switching behavior

The study reports that E20 SNPs are neutral or negatively charged at physiological pH and become positively charged under acidic formulation/endosomal conditions.

R18 apparent-pKa and pH-dependent zeta-potential experiments · Main article Figure 2b; SI Figures S78-S80

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetLiang D, Qi Y, Han H, et al. Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. Published online September 8, 2026. DOI: 10.1038/s41565-026-02262-6
Structure: main Figure 2a and SI Figures S6, S14 and S51; formulation and N/P ratio: SI Section 4.1 and Table S1; performance: main Figures 2-5 and the cited SI figures.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	10.9835 mL	2.1967 mL	1.0983 mL
25 mg	27.4586 mL	5.4917 mL	2.7459 mL
50 mg	54.9173 mL	10.9835 mL	5.4917 mL
100 mg	109.8346 mL	21.9669 mL	10.9835 mL
250 mg	274.5865 mL	54.9173 mL	27.4586 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

E20

Pack size & price

Description & Application

Recommended Products

CICL-207

5A2-SC8

LIPID 331

Lipid 29d

Lipid 119-23

Si5-N14

LUMI6

6Ac1-C12

4A3-SC7​​

306-N16B